# US 5,700,635 A · HIV-1 gag cytotoxic T-lymphocyte epitope and method of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,700,635 A
- Document ID: US5700635A
- Status: Granted
- Kind: A
- Application number: 08/359,000
- Filed: 1994-12-19
- Granted: 1997-12-23
- Earliest claimed: 1989-08-09
- Assignees: United Biomedical, Inc.
- Inventors: Andrew James McMichael; Douglas Fraser Nixon; Alain Robert Michael Townsend
- Web page: https://patentgrep.com/patent/US5700635A

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A novel human immunodeficiency virus type 1 (HIV-1) cytotoxic T-lymphocyte (CTL) epitope has been identified in the gag coding region. This epitope corresponds to amino acids 255-269 of Gag and has the following sequence: NH.sub.2 -asn-pro-pro-ile-pro-val-gly-glu-ile-tyr-lys-arg-trp-ile-ile-COOH. This peptide interacts specifically with human leukocyte antigen-B8 (HLA-B8). This peptide is useful for the identification HIV-1 gag-specific CTL.

## Claims

### Claim 1

A peptide having the amino acid sequence NH.sub.2 -asparagine-proline-proline-isoleucine-proline-valine-glycine-glutamate-is oleucine-tyrosine-lysine-arginine-tryptophan-isoleucine-isoleucine-COOH.

### Claim 2

A composition comprising:
(i) a peptide having the amino acid sequence NH.sub.2 -asparagine-proline-proline-isoleucine-proline-valine-glycine-glutamate-is oleucine-tyrosine-lysine-arginine-tryptophan-isoleucine-isoleucine-COOH; and
(ii) a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said peptide is in solution.

### Claim 4 (depends on 2)

The composition of claim 2, wherein said peptide is bound to a solid support.

### Claim 5 (depends on 2)

The composition of claim 2, wherein said peptide is mixed with an adjuvant.

### Claim 6

A method of assaying a sample for the presence of HIV-specific cytotoxic T lymphocytes, said method comprising the following steps:
(i) obtaining and preparing a sample comprising peptide-specific CTL effector cells wherein said peptide has the sequence NH.sub.2 -asparagine-proline-proline-isoleucine-proline-valine-glycine-glutamate-is oleucine-tyrosine-lys ine-arginine-tryptophan-isoleucine-isoleucine-COOH;
(ii) obtaining and preparing labeled HLA class I matched target cells;
(iii) admixing the effector cells and target cells; and
(iv) determining the amount of label released by said target cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein said labeled HLA class I matched target cells have been incubated with .sup.51 Cr.